In addition to the above metabolic outcomes, GLP-1R agonists are able to induce sustained weight loss through appetite suppression and delayed gastric emptying, ultimately leading to the commercialization of the once daily liraglutide for chronic weight management in patients with obesity [4]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.